Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

EMA recommends extension of indications for pirtobrutinib
Дата публикации: 25-09-2026 07:00:00

New indication concerns the treatment of adult patients with CLL

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1EMA Recommends Granting a Marketing Authorisation for Ensartinib013.6109-10-2026
2EMA recommends granting a marketing authorisation for relacorilant09.2502-10-2026
3FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer014.7923-09-2026
4Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS08.7130-09-2026
5FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma015.4307-10-2026
6A new treatment has been approved for extensive-stage small cell lung cancer07.6624-09-2026
7FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma012.1430-09-2026
8Un nuevo paradigma del mieloma múltiple con más calidad de vida06.4805-10-2026
9Tambotatug pelitecan leads to better clinical outcomes than topotecan among patients with relapsed SCLC after platinum-based therapy014.5528-09-2026
10Europa amplía el uso de un fármaco para tres enfermedades inmunomediadas06.6906-10-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.86. Источник: www.esmo.org.